T umor suppressor genes are those that, when functioning normally, prevent the development of tumors; losses of their normal functions (inactivation) are required for tumorigenesis. Allelic losses, gene mutations, and cryptic deletions are often detected as mechanisms involved in the inactivation of tumor suppressor genes. In addition, hypermethylation of promoter regions of genes is considered another important mechanism for down-regulation or "silencing" of the genes. Tumor suppressor genes can be subdivided into two groups: genes that directly regulate tumor growth by inhibiting cell proliferation or promoting cell death ("gatekeepers") and genes whose inactivation causes genetic instability, which in turn leads to mutations that promote tumor growth ("caretakers") (Kinzler and Vogelstein, 1998) . p53, WT1, NF1, APC, VHL, BRCA1, BRCA2, p16 INK4A /p14 ARF , and p15 INK4B genes are now included as members in the growing list of human tumor suppressor genes (Hooper, 1998) .
The warts (also referred to as LATS) was identified based on its ability to act as a tumor suppressor gene in Drosophila. A human homolog of this gene, h-warts/ LATS1, has recently been isolated (Nishiyama et al, 1999; St John et al, 1999; Tao et al, 1999) . h-warts/ LATS1 encodes a putative serine/threonine kinase, which is phosphorylated in a cell cycle-dependent manner and forms a complex with CDC2 in early mitosis, suggesting its function as a negative regulator of CDC2/cyclin complexes during cell division Nishiyama et al, 1999; Tao et al, 1999) . Notably, h-warts/LATS1-deficient (Lats1 Ϫ/Ϫ ) mice spontaneously develop ovarian stromal tumors and soft tissue sarcomas and have a significant susceptibility to induction of the latter tumors . Except for p53-deficient or p16 INK4A -deficient mice (Serrano et al, 1996; Williams and Jacks, 1996) , few animal models lacking tumor suppressor genes have been reported to be sensitive to sarcoma development. Besides, the status of the h-warts/LATS1 in human neoplasms has not been investigated, except for one recent study on gene mutations in human breast cancer (Morinaga et al, 2000) .
In this study, the role of h-warts/LATS1 as a human suppressor gene was assessed by investigating its molecular alterations in human soft tissue sarcomas. structure of the remaining 3' tail following the serine/ threonine kinase domain was not determined in this study. All the intronic donor and acceptor splice sites conformed to the consensus GT-AG mRNA splice sites (Table 1) . The sequence coding the putative serine/ threonine kinase domain spanned four distinct exons.
Gene Expression of h-warts/LATS1 in Soft Tissue Sarcomas
In our multiplex PCR using cDNAs from the 50 tumor samples, 6 (2 leiomyosarcomas, 3 myxoid liposarcomas, and 1 malignant fibrous histiocytoma [MFH] ) had no detectable gene expression of the h-warts/LATS1 (Fig. 2, Table 2 ). In addition, another leiomyosarcoma had unequivocally reduced gene expression (Fig. 2) . Identical results were obtained in another PCR using a different primer set of the h-warts/LATS1 (Fig. 2) .
Analyses of h-warts/LATS1 Alterations
To determine the molecular mechanisms of the downregulated h-warts/LATS1 expression in the seven sarcomas, allelic losses of 6q23-25.1 were first analyzed using five microsatellite markers for chromosome 6q23-25.1. All seven sarcomas were informative for this analysis, and an allelic loss of this chromosomal locus was identified in the leiomyosarcoma with reduced gene expression in RT-PCR (Fig. 3) . 
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In PCR-single-strand conformation polymorphism (SSCP) for gene mutations, two leiomyosarcomas showed point mutations in the coding regions of the h-warts/LATS1: a missense mutation at codon 566 (CAA3 CGA, Gln3 Arg) and a silent mutation at codon 1002 (GAT3 GAC) (Fig. 4) . Four sarcomas (2 myxoid liposarcomas, 1 leiomyosarcoma, and 1 MFH) with obvious gene expression in RT-PCR were also included in this analysis, but no gene mutation was identified. In Southern blot analysis of 4 sarcomas lacking gene expression (2 myxoid liposarcoma, 1 leiomyosarcoma, and 1 MFH), no aberrant bands suggesting genomic rearrangements of the h-warts/ LATS1 were found. No genomic amplification or deletion of the h-warts/LATS1 was identified either.
Although the CpG dinucleotide frequency in the human genome is nearly 0.6%, the 5' region of the h-warts/LATS1 has clustered CpG dinucleotides, suggesting its 5' regulatory element. Using a promoter scanning program, we found a putative promoter sequence located approximately 250 to 500 bp upstream of exon 1. We therefore investigated the methylation status of this region in 13 sarcomas, including 6 sarcomas with the obvious expression of the h-warts/LATS1 as controls. Aberrant hypermethylation of the putative promoter of the h-warts/ LATS1 was identified in all but one sarcoma with reduced or no gene expression (Fig. 5) . In the six sarcomas with gene expression, the promoter region was not hypermethylated. Summarized results
Figure 2.
Gene expressions of soft tissue sarcomas analyzed by RT-PCR for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and the sequences flanking exons 4 to 5 (upper panel) and 5 to 6 (lower panel) of the h-warts/LATS1. Six sarcomas (cases 3, 5, 6, 7, 10, and 12) have no detectable expression of the h-warts/LATS1, and one (case 11) has reduced gene expression compared with that of GAPDH. Lanes 1 to 4 ϭ malignant fibrous histiocytomas; lanes 5 to 8 ϭ myxoid liposarcomas; lanes 9 to 12 ϭ leiomyosarcomas; lane 13 ϭ synovial sarcoma; PBC ϭ peripheral blood mononuclear cells, M ϭ 100-bp DNA ladder. of the molecular studies of the seven sarcomas examined are shown in Table 3 .
Discussion
The tumor suppressor genes are considered to play a crucial role in development and/or progression of a wide variety of human neoplasms, and p53, RB-1, and p16 INK4A /p14 ARF are the genes frequently investigated in human sarcomas. Abnormalities of the p53 pathway occur in nearly 50% of human carcinomas and, to a lesser extent, in sarcomas (Greenblatt et al, 1994; Latres et al, 1994; Leach et al, 1993) . Aberrations in the Rb-cyclin D pathway are common in certain types of sarcomas, such as leiomyosarcoma, myxoid liposarcoma, and osteosarcoma (Benassi et al, 1999; Dei Tos et al, 1996 , 1997 . In addition, p53-deficient or p16INK4A-deficient mice frequently develop spontaneous sarcomas (Serrano et al, 1996; Williams and Jacks, 1996) .
The recently identified human homolog of Drosophila tumor suppressor h-warts/LATS1 protein is localized to the mitotic apparatus and interacts with Cdc2 kinase and zyxin, a regulator of actin filament assembly during mitosis Nishiyama et al, 1999; Tao et al, 1999) . h-warts/LATS1 is a member of the subfamily of protein kinases including dbf2, orb6, cot-1, ndr, and kpm, which are involved in cell cycle regulation and morphogenesis (Hori et al, 2000) . Dis- A, PCR-single-strand conformation polymorphism (SSCP) for gene mutation, showing aberrant bands (arrowheads) in two leiomyosarcomas (T) (cases 10 and 11). N ϭ nontumor tissue of the corresponding case; B, point mutations by sequencing of the PCR products extracted from the aberrant bands. An antisense cDNA sequence is shown in #11. ruption or abrogation of h-warts/LATS1 function may lead to an impaired mitotic process, potentially causing chromosomal or genetic instability, and/or dysregulation of the cell cycle by uncontrolled Cdc2/ cyclin A function. The h-warts/LATS1 has been shown to be ubiquitously expressed in normal fetal and adult tissues . Therefore, the h-warts/ LATS1 seems to act as a human tumor suppressor gene, and development of soft tissue sarcomas and ovarian stromal tumors in mice deficient of m-LATS1 protein (Lats1 Ϫ/Ϫ ) further reinforces this notion. Moreover, significant susceptibility to soft tissue sarcoma induction by carcinogens in these knockout mice has been documented . However, phenotypic differences may be present between human and such animal models because, for example, mice heterozygous for a null mutation in the RB-1 do not develop retinoblastoma or osteosarcoma, which are the major heterozygote phenotypes in humans, but develop pituitary tumors (Jacks et al, 1992) . Although recent molecular studies have shown that overexpression or ectopic expression of h-warts/ LATS1 significantly suppressed the growth of human tumor cells such as carcinoma cells and glioblastoma cells (Xia et al, 2002; Yang et al, 2001) , human mesenchymal tumor cells have not been examined. Thus, we focused our study on human soft tissue sarcomas.
To date, little information regarding the status of the h-warts/LATS1 in clinical samples of human neoplasms is available. Only a recent molecular analysis by (Morinaga et al, 2000) has shown that no gene mutation was identified in 25 human breast cancer tissues by their RT-PCR-SSCP, and one patient had a loss of heterozygosity of the h-warts/LATS1. However, they did not fully address the inactivation of this gene in such a human epithelial malignancy.
When we initiated this study, the genomic structure of the h-warts/LATS1 had not been well characterized.
We examined intron-exon boundaries by comparing genomic DNA and cDNA sequences spanning 75% of h-LATS1 mRNA or 95% of its coding sequence recorded in GenBank. Seven junctions between different exons were identified in the genomic region analyzed, and one of them was located in its 5'-uncoding region. This genomic characterization of the h-warts/ LATS1 facilitated the design of primers in our RT-PCR for gene expression.
In this study, various molecular approaches were conducted to investigate the prevalence of the inactivated or down-regulated h-warts/LATS1 as well as their underlying mechanisms in human soft tissue sarcomas. We found that 14% of the soft tissue sarcomas examined were shown to have downregulated gene expression, suggesting a biologic role of the h-warts/LATS1 as a human tumor suppressor gene.
Like other tumor suppressor genes, the inactivation of the h-warts/LATS1 potentially involves three major mechanisms: allelic losses or deletions of the gene, gene mutations, and hypermethylation of its promoter region. In the current analysis, only one leiomyosarcoma with reduced gene expression demonstrated an allelic loss of 6q23-25.1. The low frequency of allelic alterations in our series might reflect the fact that aberrations of 6q have been only rarely detected in human soft tissue sarcomas. A recent study using comparative genomic hybridization showed DNA copy number changes in 6q in leiomyosarcomas, although they were mostly gains (El-Rifai et al, 1998) . Interestingly, deletion of 6q has been demonstrated in three myxoid/round cell liposarcomas with t(12;16) (Altungoz et al, 1995) . Because the h-warts/LATS1 alterations were almost confined to leiomyosarcoma and myxoid liposarcoma in our study, the molecular or genetic changes involving the h-warts/LATS1 may be specifically associated with these sarcoma types.
Figure 5.
A, methylation-specific PCR using genomic DNA modified with bisulfite and methylated (M) and unmethylated (U) primers. B, partial sequence of the PCR product containing CpG dinucleotides unaffected by the chemical modification (underlined), representing methylated CpG. Modified and unmodified (original) sequences without methylated bases of the corresponding region are written. In our PCR-SSCP for gene mutations, a missense mutation was detected in one leiomyosarcoma with an allelic loss of 6q23-25.1. Although such a mutation does not seem to result in down-regulation of gene expression, the product of the mutated gene may alter its biologic property, potentially leading to the inactivation of the h-warts/LATS1.
LATS1 Alterations in Soft Tissue
Methylation of cytosine residues in CpG islands is an important mechanism through which genes can be differently transcribed, and abnormal methylation patterns effect either activation (hypomethylation) or silencing (hypermethylation) of genes. Methylation status of 5' promoter regions of tumor suppressor genes such as the p16
INK4A /p14
ARF has been recently assessed in various human malignancies. Hypermethylation-induced inactivation of the tumor suppressor genes has been detected in variable proportions of human sarcomas; for example, the prevalence of the hypermethylated p16
INK4A
/p14 ARF has varied, ranging from 0% to more than 50% in osteosarcoma (Benassi et al, 1999; Wei et al, 1999 ).
Because our molecular analyses for allelic losses, gene mutation, and genomic rearrangements failed to identify abnormalities potentially leading to the downregulation of the h-warts/LATS1 expression in six of the seven sarcomas, we then performed methylationspecific PCR of the 5' putative promoter region containing CpG islands to verify hypermethylationinduced inactivation of the h-warts/LATS1 in the sarcomas. As we expected, hypermethylation of this region was identified in the six sarcomas without gene expression in RT-PCR, supporting an alternative mechanism in inactivation of the h-warts/LATS1. Although unmethylated sequences were also amplified by our PCR in these sarcomas, it is unknown if they were a result of incomplete hypermethylation of the h-warts/LATS1 or contamination of non-neoplastic tissue in the samples examined.
In conclusion, molecular abnormalities of the h-warts/ LATS1 in subsets of human soft tissue sarcomas suggest its functional role as a human tumor suppres- a Position defined according to the sequences of Homo sapiens LATS homolog 1 mRNA (GenBank no. NM_004690) and human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA (#M33197).
b Sequence differences between modified primers and unmodified DNA are in boldface type, and differences between methylated/modified and unmethylated/ modified are underlined.
sor. Although clinical significance of the h-warts/ LATS1 remains to be determined, our findings could expand the variety of tumor-associated gene alterations involved in human mesenchymal malignancies.
Materials and Methods
Fifty cases of soft tissue sarcomas were retrieved from the files of the Department of Pathology and Oncology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. Diagnoses of the tumors were established by the combination of morphologic, immunohistochemical, and clinical features. Molecular findings such as the presence of tumor-specific fusion gene transcripts were referred to in the diagnoses of selected tumors (SYT-SSX in synovial sarcoma, EWS-FLI1/ERG in the Ewing/PNET family of tumors, TLS-CHOP in myxoid liposarcoma, and TAFII68-CHN in extraskeletal myxoid chondrosarcoma). Genomic DNA and total RNA were extracted from frozen tumor tissues and peripheral blood mononuclear cells (PBMC) provided by a healthy volunteer according to standard procedures. In a microsatellite marker analysis, DNA was isolated separately from neoplastic and non-neoplastic areas of formalin-fixed, paraffin-embedded tumor tissues by microdissection of tissue sections lightly stained with hematoxylin.
PCR, RT-PCR, and DNA Sequencing
After a treatment of DNase I (Life Technologies, Inc., Rockville, Maryland), 1 to 2 g of the extracted total RNA was reverse transcribed into cDNA using a random primer and SuperScript II reverse transcriptase (Life Technologies, Inc.) according to the manufacturer's instructions. In the molecular analyses of this study, standard PCR was performed using 0.5 l of template DNA or cDNA, 2.5 U of Taq DNA polymerase (AmpliTaq Gold; Perkin Elmer, Norwalk, Connecticut), 1.5 mM MgCl 2 , 10ϫ PCR buffer (Perkin Elmer), 200 mM deoxynucleotide triphosphates, and 0.2 mM each of forward and reverse primers. A PC-801 thermal cycler (Astec Co., Shimen, Japan) was used for the PCR amplification. PCR products were cloned into a pCR2.1 vector using a TA cloning kit (Invitrogen, San Diego, California) and sequenced by an automated sequencing system (ALFexpress DNA sequencer; Pharmacia Biotech, Uppsala, Sweden).
Genomic Characterization of h-warts/LATS1
Based on the reported sequence of h-warts/LATS1 mRNA (GenBank Accession No. NM_004690), 18 sets of primers (Table 4) were designed to amplify segments ranging from 155 to 245 bp in length and spanning most (positions 380 to 3607) of the mRNA sequence including a 5'-uncoding region (positions 380 to 548) and the putative serine/threonine kinase domain (positions 2661 to 3575). Using the genomic DNA and cDNA of PBMC, multiple PCR was performed to find junctions between different exons under the conditions of 94°C for 9 minutes followed by 40 cycles at 94°C for 30 seconds, 56°C for 30 seconds, and 72°C for 45 seconds, and final extension at 72°C for 10 minutes. In the segments with no detectable bands by the standard PCR of genomic DNA, long-range PCR using 5 U of TaKaRa LA Taq polymerase (Takara Shuzo Co., Ohtsu, Japan) was performed to more effectively amplify this region of the genomic DNA. The exact positions of the junctions between exons and sequences at the intron-exon boundaries were determined by DNA sequencing of the PCR products by referring to unpublished human DNA sequences of chromosome 6, which had been submitted directly to GenBank (Accession Nos. AL583963 and AL358852).
Expression Analysis of h-warts/LATS1
RT-PCR was performed to amplify both h-warts/ LATS1 and human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene transcripts in the same microtubes. Two sets of primers (LATS1-13 and 16) (Table 4) flanking the regions including the junctions between different exons were selected to differentiate PCR products from amplified genomic DNA contamination. The PCR conditions were mostly the same as described above. In repeated preliminary RT-PCR, the number of cycles for the PCR reaction was chosen to remain within the exponential phase of the reaction and to avoid exceeding the limit of comparable intensities of the staining with ethidium bromide after gel electrophoresis. The tumors with no or unequivocally less intense bands compared with reference bands of GAPDH were regarded as down-regulated h-warts/ LATS1 expressions.
Microsatellite Marker Analysis of 6q23-25.1
The following five dinucleotide (CA) repeat markers, listed in order from centromere to telomere, were analyzed by PCR: D6S1587, D6S471, D6S978, D6S1564, and D6S1687. The sequences of these satellite markers are distributed within a region of approximately 16 Mbp in length at chromosome 6q23-25.1, to which the h-warts/LATS1 is localized (Nishiyama et al, 1999) . The sequences of the PCR primers for these markers are available from the Genome Database (http://www.gdb.org). Forty cycles for the PCR reaction were used in this assay. The PCR products were loaded onto polyacrylamide gels and then stained with silver (Bio-Rad, Hercules, California).
Mutation Analysis of h-warts/LATS1
To screen gene mutations in most of the coding sequence of the h-warts/LATS1, SSCP was analyzed after the PCR using genomic DNA or cDNA with the above 18 sets of primers. The PCR products were heat denatured and loaded onto polyacrylamide gels at 15°C for 90 minutes with a peltier temperatureregulated electrophoresis unit (Genephor; Pharmacia Biotech). The gels were visualized with silver, and aberrant bands were removed from the gels. Gene mutations were further confirmed by DNA sequencing of the extracted PCR products from the aberrant bands. DNA with the same alteration in different clones was considered to be mutated.
Southern Blot Analysis for Gene Rearrangement
Ten micrograms of high molecular weight DNA of tumor tissues were digested with 100 U of restriction enzymes (EcoRI, HindIII, HaeIII) and loaded onto 1% agarose gels. After treatment with 0.25 M HCl, the digested DNA was transferred to positively charged nylon membranes (Amersham Pharmacia Biotech, Tokyo, Japan) and hybridized with an alkaline phosphatase-labeled probe for h-warts/LATS1 cDNA flanking the serine/threonine kinase domain (980 bp) that was generated by PCR. Detection of hybridized signals was made by an enhanced chemiluminescence detection system (AlkPhos Direct; Amersham Pharmacia Biotech).
Methylation Analysis of CpG Islands in h-warts/LATS1 Promoter
To identify a putative promoter sequence in the 5' region of the h-warts/LATS1, a genomic sequence (approximately 2 kb in length) including a part of exon 1 was analyzed by a computer-based online program (PROSCAN Ver 1.7, http://bimas.dcrt.nih.gov/molbio) (Prestridge, 1995) . The methylation status of CpG dinucleotides (islands) in the 5' putative promoter region of the h-warts/LATS1 was assessed by methylation-specific PCR using primer sets for methylated and unmethylated sequences of genomic DNA modified with bisulfite (CpGenome DNA Modification Kit; Invitrogen, Purchase, New York) (Herman et al, 1996) . Sequences of the primers used are shown in Table 4 . The modified DNA was amplified by the PCR under the conditions of 40 cycles of 94°C for 15 seconds, 56°C (methylated) or 53°C (unmethylated) for 15 seconds, and 72°C for 30 seconds. Sequences of the PCR products were confirmed by DNA sequencing.
